StrateGIST 3

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Oct 29, 2025 → Oct 7, 2026

Cited window

Mar 20, 2026 → Oct 7, 2026

Retrieved

Oct 31, 2026

Title

A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)

Registry

NCT07218926

Study IDs

300383 · 2025-522229-37-00

Sponsor

GlaxoSmithKline

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

450 estimated

Registered

2025-10-21

Start

2025-12-03 actual

Primary completion

2028-05-30 estimated

Primary endpoint

Progression-Free Survival (PFS)

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a view on early-line tolerability, activity and evidence limitations informing treatment selection after imatinib.
• –Not yet captured in this edition: a view on mutation coverage and combination alternatives for second-line treatment of advanced GIST.
• –Not yet captured in this edition: a view on timely trial referral and continuing imatinib before switching second-line treatment.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –48 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are not a representative HCP sample. Repeated posts and reposts should not be counted as independent views or consensus.
• –Some potentially relevant social posts and replies were not fully assessed, and some referral material had unresolved author attribution. Additional relevant views may be missing.
• –No exact-trial results publication was identified. No separate protocol or exact IDRX-42 regulatory label was available; comparative efficacy, comparative safety and regulatory outcomes cannot be concluded from this discussion.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Three speakers are each described in the source as involved in StrateGIST 3. Their favorable outreach is not treated as independent external validation.
• –Several clinical statements concern other studies, exploratory subgroups, practice experience or a presented case. Their relevance is to the post-imatinib decision, not to observed StrateGIST 3 outcomes.
• –The discussion of repeat molecular testing, specific combination choices and approval timing is incomplete; it should not be read as a comprehensive account of those recommendations or forecasts.
• –Publication and post dates establish when material appeared, not necessarily when a session occurred, results were presented or an opinion changed.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "StrateGIST 3" (NCT07218926), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "strategist-3-07218926". If you cannot make requests, read https://www.erudio.com/reports/strategist-3-nct07218926.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT07218926", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct07218926 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/strategist-3-nct07218926.json
curl https://www.erudio.com/reports/strategist-3-nct07218926.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "strategist-3-07218926" })